Activating point mutations in IGF1R itself have not been reported, but there are reports of mutational inactivation or loss of heterozygosity of the anti-proliferative IGF2R in prostate cancer and uveal melanoma [44,45]. The gene discussed is IGF1R; the disease is Familial prostate cancer.